Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
43 results about "U937 cell" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
U937 cells are a model cell line used in biomedical research. They were isolated from the histiocytic lymphoma of a 37-year-old male patient and are used to study the behaviour and differentiation of monocytes. U937 cells mature and differentiate in response to a number of soluble stimuli, adopting the morphology and characteristics of mature macrophages.
Method for preparing Bailing tablets and application
InactiveCN102988526AReduce dosagePill deliveryAntineoplastic agentsSaposhnikoviaTraditional medicine
The invention provides a method for preparing Bailing tablets. The Bailing tablets are prepared from 194g of Chinese angelica, 42g of pseudo-ginseng, 83g of safflower, 167g of peony bark, 83g of peach kernel, 167g of divaricate saposhnikovia root, 167g of atractylodes, 42g of angelica root, 417g of purslane, 83g of red peony root and 194g of astragalus root serving as raw medicaments by adopting supercritical extraction and microwave extraction, so that the ferulic acid content is greatly improved. The invention also provides application of the Bailing tablets in preparation of a medicament for inhibiting propagation of human histiocytic lymphoma U937 cells.
Owner:李宽 +1
Ursolic acid derivative and preparation method thereof
The invention relates to an ursolic acid derivative and a preparation method thereof. The ursolic acid derivative is 3-beta-acetoxy-ursolic alkyl-12-alkene-28-acyl (8'-aminobutyric acid) or 3-beta-acetoxyl-ursolic alkyl-12-alkene-28-acyl (4'-aminobutanol). The preparation method comprises the following steps of: converting ursolic acid into coarse 3-O-acetyl ursolic alkyl-28-acyl chloride intermediates via two steps, and making the coarse products as one of reactants react with 8-amino octanoic acid or 4-amino butanol, thereby obtaining the ursolic acid derivative. The ursolic acid derivativehas good effects on inhibition of human leukemia U937 cell proliferation, which cannot be realized by the prior art. The synthesis reaction steps in the technical scheme are reduced, the purificationmethod is simple, the cost can be reduced, and the product purity is high.
Owner:ARMY MEDICAL UNIV
Polyoxometalate compound modified by amino acid and preparation method and application of polyoxometalate compound
ActiveCN105732409ASolve the problem of low anti-leukemia activityHigh activityOrganic chemistryAntineoplastic agentsHl 60 cellArginine
The invention discloses a polyoxometalate compound modified by amino acid.The compound has the general formula of Am[B3XMo6O21].nH2O and is prepared through the steps of dissolving Na2MoO4.H2O, Se, As, Sb or Bi oxide, glycine, alanine, histidine, lysine, tryptophan, phenylalanine, methionine, threonine, isoleucine, leucine or arginine and KCl in H2O, putting the solution on a magnetic stirrer to be mixed and stirred, adjusting pH of the solution to be 3.4 to 3.6 through HCl, stirring and heating reflux for 0.5-2 hours, conducting cooling and filtering, standing for 1-2 days, and collecting crystals.It is determined through the MTT method that the IC50 value of HL-60 cells is 0.127 microM, the IC50 value of U937 cells is 2.731 microM, the IC50 value of U937 cells is 2.731 microM, and the IC50 value of HUVECs cells is 889.18 microM.The polyoxometalate compound is high in leukemia resistant activity, low in toxicity and low in price.
Owner:JILIN UNIV
Preparation method and application of osteoproliferation removal tablets
PendingCN104940426AHigh in active ingredientsPill deliveryAntineoplastic agentsAdditive ingredientOsteoproliferation
The invention belongs to the field of traditional Chinese medicine preparations, and particularly provides a preparation method of osteoproliferation removal tablets. The osteoproliferation removal tablets comprise the active pharmaceutical ingredients of 208 g of prepared rehmannia roots, 140 g of caulis spatholobi, 140 g of herba epimedii, 140 g of rhizoma drynariae, 140 g of rhizoma cibotii, 70 g of semen raphani, 70 g of wolfberry fruits, 140 g of cynomorium songaricum and 70 g of himalayan teasel roots. The osteoproliferation removal tablets are prepared from cationic resin in a supercritical extraction mode, the content is greatly increased, and the dosage is decreased. The invention further provides the application of the osteoproliferation removal tablets in preparing medicine for restraining proliferation of human tissue cell lymphoma U937 cells.
Owner:JILIN ZHENGHE PHARMA GRP
Histone deacetylases inhibitor
The invention provides a histone deacetylases (HDACs) inhibitor compound N<1>-(6-(hydroxyamino)-6-oxohexyl)-N<4>-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)terephthalamide having an obvious inhibitory effect on both HDACs and human leukemia U937 cell growth and proliferation, wherein the inhibitory effect is significantly stronger than that of a common HDACs inhibitor trichostatin TSA. The invention also provides a preparation method and a process route of the compound.
Owner:孙勇
Process for preparing anti-tumor oligosaccharide material from chitosan
InactiveUS20080097086A1Organic active ingredientsSugar derivativesHuman leukemiaEnzymatic hydrolysis
The present invention relates to a process for preparing chito-oligosaccharide material by the enzymatic hydrolysis of chitinous materials, such as chitin, chitosan, and squid pen. The results of cell experiment showed that the oligosaccharide material of the invention causes a decrease in survival rate of U937 cell (a human leukemia cell line) to 69-57%; and of CT26 (a mouse rectal carcinoma cell line) to 69-57%. The product of the invention is preferably in form of tablet, capsule, powder, and granules. It may be added to any kind of foods as a nutriment, which is administered orally as an anti-tumor auxiliary.
Owner:TENWELL BIOTECH
Preparation method and applications of bupleurum tenue capsule
ActiveCN103977391ARich in active ingredientsReduce dosageCapsule deliveryAntineoplastic agentsCodonopsis pilosulaRed blood cell
The invention provides a preparation method of a bupleurum tenue capsule. The bupleurum tenue capsule is prepared from the following active pharmaceutical ingredients: 445g of bupleurum tenue, 222g of pinellia ternata stir-baked with ginger juice, 167g of scutellaria baicalensis, 167g of codonopsis pilosula, 167g of liquorice, 167g of fresh ginger and 167g of Chinese dates. The bupleurum tenue capsule is prepared by means of supercritical extraction, so that the content of active ingredients is increased greatly and the dosage is reduced. The invention also provides the applications of the bupleurum tenue capsule in preparing medicines for inhibiting proliferation of human histocyte lymphoma U937 cells and medicines for increasing red blood cells.
Owner:云南云龙制药股份有限公司
Use of CoCl#-[2] in preparation of drug for treating leukemia
InactiveCN1522710AInhibits HIF-1α degradationInduced differentiationHeavy metal active ingredientsPill deliveryMedicineAll-trans-Tretinoin
The present invention relates to an application of CoCl2 in preparation of medicine in treating leucosis. The common low oxygen environment analog compound can effectively inhibit degradation of HIF-1 alpha in the leucosis cell so as to induce differentiation of leucosis cell. The CoCl2 can combined with arsenic troxide (ATO) and / or all-trans-tretinoin (ATRA) to make matched application. The dose range of CoCl2 is nontoxic dose, its optimum range is 12.5-5.0 micro M. The described leucosis cell can be NB4 cell, U937 cell and Kasumi cell.
![Use of CoCl#-[2] in preparation of drug for treating leukemia](https://images-eureka.patsnap.com/patent_img/8bf171d8-347e-4e9a-b776-45ad91393f94/A0315082600261.PNG "Use of CoCl#-[2] in preparation of drug for treating leukemia")
![Use of CoCl#-[2] in preparation of drug for treating leukemia](https://images-eureka.patsnap.com/patent_img/8bf171d8-347e-4e9a-b776-45ad91393f94/A0315082600262.PNG "Use of CoCl#-[2] in preparation of drug for treating leukemia")
![Use of CoCl#-[2] in preparation of drug for treating leukemia](https://images-eureka.patsnap.com/patent_img/8bf171d8-347e-4e9a-b776-45ad91393f94/A0315082600271.PNG "Use of CoCl#-[2] in preparation of drug for treating leukemia")
Owner:SHANGHAI SECOND MEDICAL UNIV
Novel endonuclease of immune cell, process for producing the same and immune adjuvant using the same
Owner:CJ CHEILJEDANG CORP
CCR5 autogenous polypeptide vaccine and preparation method thereof
The invention relates to a method for producing CCR5 autovaccine, wherein based on the structure of CCR5, it uses linker whose amino acid sequence is GGGGS to connect external four sections of CCR5 cell, to simulate the external structure as rCCR5; inserts T cell assist epitope PADRE into N end of rCCR5; artificially synthesizes PADRE- rCCR5 gene; the target gene is colon into represent carrier of pBV-220 corn; transfers bacillus coli, to represent effect in it; washes with inclusion body; chromatography in gel post; obtaining purified protein; the target protein PADRE-rCCR5 is used as CCR5 polypeptide vaccine antigen, while immunity animal represents that the PADRE-rCCR5 can induce body to generate the antibody with high CCR5 specificity; and the invention uses flow cell check immunity antiserum to test U937 cell of CCR5, which proves that the average combine rate can reach 75. 8%. The invention supports CCR5 autovaccine construction and AIDS vaccine research.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
Use of HIF-1 alpha in screen selection of medicament for treating leukemia
InactiveCN1523357ATo achieve the purpose of treating leukemiaMicrobiological testing/measurementBiological testingMedicineDrug target
The invention relates to an application of HIF-1 alpha to screening drug of inducing differentiation to cure leukemia, using HIF-1 alpha as drug target, screening the drug able to differentiate leukemic cells on the low-oxygen condition. Using HIF-1 alpha as drug target can screen cobalt chloride to differentiate leukemic cells. The leukemic cells are NB4 ones, U973 ones, Kasumi ones, various AML ones, etc.
Owner:RUIJIN HOSPITAL ATTACHED TO SHANGHAI NO 2 MEDICALUNIV
Application of GL-V9 and anthracycline antibiotics in preparation of leukemia treatment medicine
PendingCN112891341AGrowth inhibitionOrganic active ingredientsAntineoplastic agentsPharmaceutical drugNude mouse
The invention discloses application of a flavonoid derivative GL-V9 and anthracycline antibiotics in preparation of a leukemia treatment medicine, and belongs to the technical field of medicines. It is found that the flavonoid derivative GL-V9 combined with low-dose anthracycline antibiotics can significantly inhibit growth of acute myelogenous leukemia (AML) cells, MTT experiments and U937 cell nude mouse transplantation tumor models verify that the GL-V9 and the low-dose anthracycline antibiotics can play a synergistic anti-AML effect, and the application potential of the combined administration mode in treatment of AML is prompted.
Owner:CHINA PHARM UNIV
Application of panatinib in preparation of medicament for treating influenza virus infection
InactiveCN110013482AGreat clinical therapeutic potentialReduce weight lossOrganic active ingredientsAntiviralsInflammatory factorsAnti-inflammatory analgesics
The invention discloses an application of panatinib in the preparation of a medicament for treating influenza virus infection. The applicant tests the toxicity of panatinib to cells on human monocyteseries U937 and tests the secretion inhibitory effect of panatinib on the three important inflammatory factors IL-8, IP-10 and MCP-1 in U937 cell line in a non-toxic or low-toxic concentration range.The result shows that the small-molecular compound has significant anti-inflammatory activity and dose-dependent effect. In a lethal mouse influenza infection model, panatinib is used for treating infected mice, and can effectively reduce the concentration of inflammatory factors in lung lavage fluid of the infected mice, delay the reduction speed of the weight of the mice, and improve the survival rate of the mice. Therefore, the panatinib disclosed by the invention is a novel anti-inflammatory drug aiming at influenza, has the advantages of good safety, high selection index and effective animal model experiments, can be used for developing drugs for treating influenza virus infection, and has wide application prospect.
Owner:武汉威立得生物医药有限公司
Use of CoCl#-[2] in preparation of drug for treating leukemia
InactiveCN1242749CInhibits HIF-1α degradationInduced differentiationHeavy metal active ingredientsPill deliveryMedicineAll-trans-Tretinoin
The present invention relates to an application of CoCl2 in preparation of medicine in treating leucosis. The common low oxygen environment analog compound can effectively inhibit degradation of HIF-1 alpha in the leucosis cell so as to induce differentiation of leucosis cell. The CoCl2 can combined with arsenic troxide (ATO) and / or all-trans-tretinoin (ATRA) to make matched application. The dose range of CoCl2 is nontoxic dose, its optimum range is 12.5-5.0 micro M. The described leucosis cell can be NB4 cell, U937 cell and Kasumi cell.
![Use of CoCl#-[2] in preparation of drug for treating leukemia](https://images-eureka.patsnap.com/patent_img/61cf3761-ee20-4894-aeea-28b333017500/C0315082600251.PNG "Use of CoCl#-[2] in preparation of drug for treating leukemia")
![Use of CoCl#-[2] in preparation of drug for treating leukemia](https://images-eureka.patsnap.com/patent_img/61cf3761-ee20-4894-aeea-28b333017500/C0315082600252.PNG "Use of CoCl#-[2] in preparation of drug for treating leukemia")
![Use of CoCl#-[2] in preparation of drug for treating leukemia](https://images-eureka.patsnap.com/patent_img/61cf3761-ee20-4894-aeea-28b333017500/C0315082600261.PNG "Use of CoCl#-[2] in preparation of drug for treating leukemia")
Owner:SHANGHAI SECOND MEDICAL UNIV
Application of camptothecin derivative in drug preparing process for treating marrow originate leukemia
InactiveCN1663565AEnhance pharmacological effectsInhibits clonogenic activityOrganic active ingredientsAntineoplastic agentsZ-DEVD-FMKBiological activation
The present invention concerns application of camptothecine derivation NSC606985 in preparing drug for acute leukemia. NSC606985 of nano-molar concentration can induce cell line NB4 and cell U937 of leukemia to apoptosis. On the aspect of inducing apoptosis, NSC606985 can induce quickly transmembrane potential of mitochondrion (deltaWm) to falling and activation of caspase-3. Hydrolysis and activation of protein kinase induced C delta (PKC delta) by NSC606985 plays key role and starting effect during these processes. Specific inhibitor rottlerin for PKC delta can restrain entirely the falling of mitochondrion deltaWm and activation of caspase-3 and the Specific inhibitor Z-DEVD-fmk for caspase-3 just weaken partly activation of PKC delta and cell apoptosis. NSC606985 restrains marked clone forming ability of hemopoietic progenitor cell in fresh marrow of patient of acute medullary leukemia. So NSC606985 is potential active drug for treating leukemia.
Owner:RUIJIN HOSPITAL ATTACHED TO SHANGHAI NO 2 MEDICALUNIV
Application of human-derived monocytic series U937 in preparation of anti-influenza virus and drug screening model of inflammation factor induced by virus
InactiveCN107034263AIncreased sensitivityWide applicabilityMicrobiological testing/measurementMaterial analysisInflammatory factorsHigh-Throughput Screening Methods
The invention discloses application of a human-derived monocytic series U937 in preparation of an anti-influenza virus and a drug screening model of an inflammation factor induced by the virus. In the application, an influenza virus can effectively infect a U937 cell line and can induce a series of important inflammatory factor expressions including MCP-1, IP-10, IL-8, IL-6 and the like, and the toxicity and antiviral and anti-inflammatory activity of drugs can be comprehensively evaluated in a round of experiments by detecting the activity of injected cells, the virus level in supernatant and the level of relevant inflammatory factors. The established cell screening model is accurate, efficient, low in cost, short in consumed time and free of deviation property and can be used for high throughput screening of antiviral and anti-inflammatory drugs for treating the influenza virus.
Owner:WUHAN INST OF VIROLOGY CHINESE ACADEMY OF SCI
Ursolic acid derivative and preparation method thereof
The invention provides an ursolic acid derivative and a preparation method thereof. The ursolic acid derivative is bearberry alkane-12-alkene-28-acyl (8'-aminocaprylicacid). The preparation method of the ursolic acid derivative comprises the following steps: firstly, ursolic acid is converted into a crude product of a 3-O-acetyl bearberry alkane-28-acyl chloride intermediate through two steps, then the crude product is used as one of reactants to react with 8-aminocaprylicacid, and finally the crude product and a sodium hydroxide solution are subjected to hydrolysis reaction, so that the ursolic acid derivative is obtained. Compared with the ursolic acid derivative in the prior art, the ursolic acid derivative provided by the invention has more obvious and better effects on the aspect of inhibiting human body leukemia U937 cell proliferation; the preparation method has few steps, the purification method is simple, the cost can be reduced, and the product purity is high.
Owner:ARMY MEDICAL UNIV
Protein AGGF1 and application of FHA polypeptide of protein AGGF1 in preparation of anti-inflammatory drug
ActiveCN103254296AInhibition of activationReduce adhesionPeptide/protein ingredientsDepsipeptidesDiseaseInflammatory factors
The invention discloses a novel protein AGGF1 with high anti-inflammatory performance, FHA polypeptide of the protein AGGF1 and application of the FHA polypeptide in preparation of an anti-inflammatory drug, and belongs to the field of biological medicine. The FHA polypeptide represented by SEQ ID NO:1 in a sequence list and the protein AGGF1 represented by SEQ ID NO:2 in the sequence list are expressed through cloning; and effects of the FHA polypeptide and the protein AGGF1 in an endothelial cell HUVEC and mononuclear cell U937 adhesion process, effects of the FHA polypeptide and the protein AGGF1 for expressing inflammatory factors E-Selectin, ICAM and IL-8 in the endothelial cells HUVEC and effects of the FHA polypeptide and the protein AGGF1 for inhibiting the activity of an NF-kB starter are checked, so that the FHA polypeptide and the protein AGGF1 can be found to be capable of inhibiting the activation of the blood vessel endothelium and then further inhibiting the generation of vascular inflammation. Therefore, the polypeptide comprised in an amino acid sequence provided by the invention or consisting of the SEQ ID NO:1 or the SEQ ID NO:2 can be effectively used for preparing the anti-inflammatory drug and lays the foundation for the preparation of broad-spectrum anti-inflammatory drugs and the prevention or treatment of inflammation related diseases.
Owner:田小利
Application of triptonide in preparation of medicine for treating acute monocyte leukemia
PendingCN111407766ALimit concentrationAchieve inhibitionOrganic active ingredientsAntineoplastic agentsInducer CellsAcute leukemia
The invention provides application of triptonide in preparation of a medicine for treating acute monocyte leukemia, and belongs to the technical field of leukemia medicines. According to the application of the triptonide in preparation of the medicine for treating the acute monocyte leukemia, acute monocyte leukemia cells U937 are taken as research objects, U937 cells are treated by a triptonide solution, the cell activity of the U937 cells is detected by an MTT method, and the result shows that the triptonide has an effect of inhibiting proliferation of the U937 leukemia cells. The influenceof the triptonide on apoptosis of the U937 cells is detected by an Annexin V / PI double staining method, and the result shows that the triptonide can induce apoptosis of the U937 cells, and the apoptosis is more obvious along with increase of concentration. Therefore, the triptonide can inhibit proliferation of the acute leukemia cells and induce apoptosis, so that treatment of the acute monocyte leukemia is realized.
Owner:INST OF CHINESE MATERIA MEDICA CHINA ACAD OF CHINESE MEDICAL SCI
Method of Treating Leukemia Using Rcie Prolamin
InactiveUS20110183918A1Growth inhibitionConcern of side effectPeptide/protein ingredientsArtificial cell constructsHuman leukemiaTumor necrosis factor alpha
The present invention relates to a method of treating leukemia using rice prolamin, and a pharmaceutical composition for treating leukemia, comprising an effective amount of rice prolamin together with one or more pharmaceutically acceptable carriers or excipients. For the treatment application, the rice prolamin can stimulate human peripheral blood mononuclear cell (PBMC) to produce cytokines, such as tumor necrosis factor-alpha, to inhibit growth of and induce differentiation of human leukemia U937 cells. The rice prolamin is gluten-free, thus will not trigger gastrointestinal allergic reaction.
Owner:MACKAY MEMORIAL HOSPITAL
Ursolic acid derivative and preparation method thereof
The invention discloses an ursolic acid derivative and a preparation method thereof. The ursolic acid derivative is ursolic acid-12-alkene-28-acyl(7'-aminoheptylic acid) or ursolic acid-12-alkene-28-acyl(paraaminomethylbenzoicacid). The preparation method comprises the following steps of: transforming ursolic acid into a crude product of a 3-O-acetyl ursolic acid-28-acyl chloride intermediate in two steps; reacting with 7-amino ethyl heptylate hydrochloride or paraaminomethylbenzoicacid methyl ester hydrochloride by taking the crude product as one of reactants; and hydrolyzing with a sodium hydrate aqueous solution to obtain the ursolic acid derivative. The ursolic acid derivative has a good effect on inhibiting the human leukemias U937 cell proliferation which is not achieved in the prior art; and the preparation method has the advantages of small quantity of synthesis reaction steps, simple purification method, saving in cost and high product purity.
Owner:ARMY MEDICAL UNIV
An immune cell line with enhanced antitumor effect
ActiveCN112442485BGrowth inhibitionHigh self-proliferation rateMammal material medical ingredientsBlood/immune system cellsMelanomaCARCINOMA COLON
The invention relates to the field of cellular immunotherapy of tumors, in particular to enhancing the anti-tumor effect of immune cells by modifying specific genes of immune cells, specifically reducing the expression of PRNP gene (prion protein, PrP, prion protein) by technical means to Enhance the anti-tumor effect of immune cells. By knocking down PrP in human histiocytic lymphoma U937 cell line, an immune cell line with low PrP expression was obtained. The cell line has an enhanced ability to inhibit the growth of human or mouse colon cancer and melanoma cells, and the immune cell line is induced by tumor cells to increase the level of self-cell growth.
Owner:EAST CHINA NORMAL UNIV
Method for preparing Bailing tablets and application
The invention provides a method for preparing Bailing tablets. The Bailing tablets are prepared from 194g of Chinese angelica, 42g of pseudo-ginseng, 83g of safflower, 167g of peony bark, 83g of peach kernel, 167g of divaricate saposhnikovia root, 167g of atractylodes, 42g of angelica root, 417g of purslane, 83g of red peony root and 194g of astragalus root serving as raw medicaments by adopting supercritical extraction and microwave extraction, so that the ferulic acid content is greatly improved. The invention also provides application of the Bailing tablets in preparation of a medicament for inhibiting propagation of human histiocytic lymphoma U937 cells.
Owner:李宽 +1
Application of dasatinib in preparing drugs for treating influenza virus infection
InactiveCN110314162AGreat clinical therapeutic potentialReduce weight lossOrganic active ingredientsAntipyreticInflammatory factorsDasatinib
The invention discloses application of dasatinib in preparing drugs for treating influenza virus infection. The toxicity of the dasatinib on cells is detected on a human monocytic line U937, then within the concentration range of nontoicity or low toxicity, the secretion inhibition effect of the dasatinib on three important inflammatory factors of IL-8, IP-10 and MCP-1 in the cell line U937, and results show that the small-molecular compound has significant anti-inflammatory activity and shows a doseage-dependent effect. In a fatal mouse influenza infection model, the dasatinib is utilized fortreating an infected mouse, the concentration of the inflammatory factors in lung washing liquid of the mouse can be effectively lowered, the weight lowering speed of the mouse is lowered, and the survival rate of the mouse is increased. Therefore, the dasatinib is a novel anti-inflammatory drug for influenza, has the advantages that the safety and selection index are high, and animal model experiments are effective, can be used for developing drugs for treating the influenza virus infection, and has a wide application prospect.
Owner:武汉威立得生物医药有限公司
Preparation method and application of perillaseed qi depressing pellet
InactiveCN103656016AReduce dosagePharmaceutical product form changePill deliveryOfficinalisLiquorices
The invention provides a preparation method of a perillaseed qi depressing pellet. The pellet is prepared from 160 g of fried perillaseed, 160 g of mangnolia officinalis, 160 g of common hogfenneI root, 160 g of liquorice, 160 g of ginger processed pinellia, 160 g of dried orange peel, 112 g of agilawood and 112 g of angelica sinensis as raw material medicines through supercritical fluid extraction. Therefore, the content is greatly increased, and the dosage is reduced. The invention further provides application of the perillaseed qi depressing pellet in preparing a medicament for inhibiting cell proliferation of human histocyte lymphoma U937.
Owner:李梅
A kind of preparation method and application of Suzijiangqi pill
InactiveCN103656016BReduce dosagePharmaceutical product form changePill deliveryOfficinalisLiquorices
The invention provides a preparation method of a perillaseed qi depressing pellet. The pellet is prepared from 160 g of fried perillaseed, 160 g of mangnolia officinalis, 160 g of common hogfenneI root, 160 g of liquorice, 160 g of ginger processed pinellia, 160 g of dried orange peel, 112 g of agilawood and 112 g of angelica sinensis as raw material medicines through supercritical fluid extraction. Therefore, the content is greatly increased, and the dosage is reduced. The invention further provides application of the perillaseed qi depressing pellet in preparing a medicament for inhibiting cell proliferation of human histocyte lymphoma U937.
Owner:李梅
Novel application of Java brucea fruit oil emulsion injection to anticancer aspect
ActiveCN101879202ALow cytotoxicitySmall toxicityEmulsion deliveryAntineoplastic agentsHl 60 cellOil emulsion
Owner:SHENYANG PHARMA UNIVERSITY
Immune cell line with enhanced anti-tumor effect
ActiveCN112442485AGrowth inhibitionHigh self-proliferation rateMammal material medical ingredientsBlood/immune system cellsMelanomaPRNP
The invention relates to the field of cellular immunotherapy of tumors, in particular, the invention relates to enhancing the anti-tumor effect of immune cells by modifying specific genes of the immune cells, specifically enhancing the anti-tumor effect of the immune cells by reducing the expression amount of PRNP genes (prion protein, PrP and prion protein) through technical means. The PrP is knocked down from a human tissue cell lymphoma cell U937 cell line to obtain an immune cell line with low PrP expression. The cell line has enhanced the inhibition capability on the growth of colon cancer and melanoma cells of human or mouse, and the growth level of autologous cells is increased after the immune cell line is induced by tumor cells.
Owner:EAST CHINA NORMAL UNIV
Endonuclease of immune cell, process for producing the same and immune adjuvant using the same
The present invention relates to a novel endonuclease enzyme which is secreted from immune cell and recognizes bacterial DNA as foreign agent and processes it to produce about 10 bp single-stranded oligonucleotide including CpG motif which is involved in immune response. Also, the present invention relates to a process for producing the endonuclease which comprises culturing human B-lymphoblastic IM9 cell line or TPA-treated myelogenous U937 cell line on an appropriate medium to produce the said endonuclease and isolating the said endonuclease from the cell lysate or the culture medium. In addition, the present invention relates to an immune adjuvant comprising about 10 bp single-stranded oligonucleotide having CpG motif produced by treatment of bacterial DNA by endonuclease.
Owner:CJ CHEILJEDANG CORP
Anti-cancer nano-drug with immune activation function and preparation method thereof
PendingCN114344277ATypical core-shell structureGood dispersionOrganic active ingredientsNanomedicineTumor targetSide effect
Owner:JILIN UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com